158 related articles for article (PubMed ID: 28034519)
1. Treatment Outcomes in Infections Caused by "SPICE" (Serratia, Pseudomonas, Indole-positive Proteus, Citrobacter, and Enterobacter) Organisms: Carbapenem versus Noncarbapenem Regimens.
Moy S; Sharma R
Clin Ther; 2017 Jan; 39(1):170-176. PubMed ID: 28034519
[TBL] [Abstract][Full Text] [Related]
2. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
[TBL] [Abstract][Full Text] [Related]
3. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
5. Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy.
Lee CC; Lee NY; Yan JJ; Lee HC; Chen PL; Chang CM; Wu CJ; Ko NY; Wang LR; Chi CH; Ko WC
Antimicrob Agents Chemother; 2010 Sep; 54(9):3551-6. PubMed ID: 20547798
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
8. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
9. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
Lu B; Wong M; Ha D; Bounthavong M; Banaei N; Deresinski S; Diep C
J Antimicrob Chemother; 2023 Apr; 78(4):1009-1014. PubMed ID: 36879495
[TBL] [Abstract][Full Text] [Related]
10. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales bacteremia in pediatric patients.
Liu YC; Lu CY; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM
J Microbiol Immunol Infect; 2023 Feb; 56(1):84-92. PubMed ID: 36376217
[TBL] [Abstract][Full Text] [Related]
12. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
Cheng L; Nelson BC; Mehta M; Seval N; Park S; Giddins MJ; Shi Q; Whittier S; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320724
[No Abstract] [Full Text] [Related]
14. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
15. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Bacteremia Caused by
Drozdinsky G; Neuberger A; Rakedzon S; Nelgas O; Cohen Y; Rudich N; Mushinsky L; Ben-Zvi H; Paul M; Yahav D
Microb Drug Resist; 2021 Mar; 27(3):410-414. PubMed ID: 32808858
[No Abstract] [Full Text] [Related]
17. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
[TBL] [Abstract][Full Text] [Related]
18. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
Harris PN; Wei JY; Shen AW; Abdile AA; Paynter S; Huxley RR; Pandeya N; Doi Y; Huh K; O'Neal CS; Talbot TR; Paterson DL
J Antimicrob Chemother; 2016 Feb; 71(2):296-306. PubMed ID: 26542304
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
